This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Breslin, T. M. Articles by Hunt, K. K. Search for Related Content PubMed PubMed Citation Articles by Breslin, T. M. Articles by Hunt, K. K.

Sentinel Lymph Node Biopsy Is Accurate After Neoadjuvant Chemotherapy for Breast Cancer

From the Departments of Surgical Oncology, Pathology, Breast Medical Oncology, and Nuclear Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Kelly K. Hunt, MD, Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box-106, Houston, TX 77030; email khunt@ mail.mdanderson.org.

PURPOSE: Sentinel lymph node (SLN) biopsy has proved to be an accurate method for detecting nodal micrometastases in previously untreated patients with early-stage breast cancer. We investigated the accuracy of this technique for patients with more advanced breast cancer after neoadjuvant chemotherapy.

PATIENTS AND METHODS: Patients with stage II or III breast cancer who had undergone doxorubicin-based neoadjuvant chemotherapy before breast surgery were eligible. Intraoperative lymphatic mapping was performed with peritumoral injections of blue dye alone or in combination with technetium-labeled sulfur colloid. All patients were offered axillary lymph node dissection. Negative sentinel and axillary nodes were subjected to additional processing with serial step sectioning and immunohistochemical staining with an anticytokeratin antibody to detect micrometastases.

RESULTS: Fifty-one patients underwent SLN biopsy after neoadjuvant chemotherapy from 1994 to 1999. The SLN identification rate improved from 64.7% to 94.1%. Twenty-two (51.2%) of the 43 successfully mapped patients had positive SLNs, and in 10 of those 22 patients (45.5%), the SLN was the only positive node. Three patients had false-negative SLN biopsy; that is, the sentinel node was negative, but at least one nonsentinel node contained metastases. Additional processing revealed occult micrometastases in four patients (three in sentinel nodes and one in a nonsentinel node).

CONCLUSION: SLN biopsy is accurate after neoadjuvant chemotherapy. The SLN identification improved with experience. False-negative findings occurred at a low rate throughout the series. This technique is a potential way to guide the axillary treatment of patients who are clinically node negative after neoadjuvant chemotherapy.

This article has been cited by other articles:

				K. E. Kilbride, M. C. Lee, A. V. Nees, V. M. Cimmino, K. M. Diehl, M. S. Sabel, D. F. Hayes, A. F. Schott, C. G. Kleer, A. E. Chang, et al. Axillary Staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence Ann. Surg. Oncol., November 1, 2008; 15(11): 3252 - 3258. [Abstract] [Full Text] [PDF]

				B. J. Grube, C. J. Christy, D. Black, M. Martel, L. Harris, J. Weidhaas, M. P. DiGiovanna, G. Chung, M. M. Abu-Khalaf, K. D. Miller, et al. Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy Arch Surg, July 1, 2008; 143(7): 692 - 700. [Abstract] [Full Text] [PDF]

				K. Shimazu, Y. Tamaki, T. Taguchi, F. Tsukamoto, T. Kasugai, and S. Noguchi Intraoperative Frozen Section Analysis of Sentinel Lymph Node in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Ann. Surg. Oncol., June 1, 2008; 15(6): 1717 - 1722. [Abstract] [Full Text] [PDF]

				P. Gimbergues, C. Abrial, X. Durando, G. Le Bouedec, F. Cachin, F. Penault-Llorca, M. A. Mouret-Reynier, F. Kwiatkowski, J. Maublant, A. Tchirkov, et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation Ann. Surg. Oncol., May 1, 2008; 15(5): 1316 - 1321. [Abstract] [Full Text] [PDF]

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				E. A. Newman, M. S. Sabel, A. V. Nees, A. Schott, K. M. Diehl, V. M. Cimmino, A. E. Chang, C. Kleer, D. F. Hayes, and L. A. Newman Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation Ann. Surg. Oncol., October 1, 2007; 14(10): 2946 - 2952. [Abstract] [Full Text] [PDF]

				D. J. Hsiang, M. Yamamoto, R. S. Mehta, M.-Y. Su, C. H. Baick, K. T. Lane, and J. A. Butler Predicting Nodal Status Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy With and Without Sequential Trastuzumab Arch Surg, September 1, 2007; 142(9): 855 - 861. [Abstract] [Full Text] [PDF]

				J.-C. Yu, G.-C. Hsu, C.-B. Hsieh, C.-P. Yu, and T.-Y. Chao Role of Sentinel Lymphadenectomy Combined with Intraoperative Ultrasound in the Assessment of Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy Ann. Surg. Oncol., January 1, 2007; 14(1): 174 - 180. [Abstract] [Full Text] [PDF]

				I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]

				M. C. van Rijk, O. E. Nieweg, E. J. T. Rutgers, H. S. A. Oldenburg, R. V. Olmos, C. A. Hoefnagel, and B. B. R. Kroon Sentinel Node Biopsy Before Neoadjuvant Chemotherapy Spares Breast Cancer Patients Axillary Lymph Node Dissection Ann. Surg. Oncol., April 1, 2006; 13(4): 475 - 479. [Abstract] [Full Text] [PDF]

				C. E. Cox, J. M. Cox, L. B. White, N. G. Stowell, J. D. Clark, N. Allred, M. Meyers, E. Dupont, B. Furman, and S. Minton Sentinel Node Biopsy Before Neoadjuvant Chemotherapy for Determining Axillary Status and Treatment Prognosis in Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2006; 13(4): 483 - 490. [Abstract] [Full Text] [PDF]

				L. A. Lambert, G. D. Ayers, R. F. Hwang, K. K. Hunt, M. I. Ross, H. M. Kuerer, S. E. Singletary, G. V. Babiera, F. C. Ames, B. Feig, et al. Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy Ann. Surg. Oncol., March 1, 2006; 13(3): 310 - 320. [Abstract] [Full Text] [PDF]

				B. T. Hennessy, G. N. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. U. Buzdar, S. W. Kau, B. Fornage, A. Sahin, K. Broglio, et al. Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy J. Clin. Oncol., December 20, 2005; 23(36): 9304 - 9311. [Abstract] [Full Text] [PDF]

				M. Intra, G. Trifiro, G. Viale, N. Rotmensz, O. D. Gentilini, J. Soteldo, V. Galimberti, P. Veronesi, A. Luini, G. Paganelli, et al. Second Biopsy of Axillary Sentinel Lymph Node for Reappearing Breast Cancer After Previous Sentinel Lymph Node Biopsy Ann. Surg. Oncol., November 1, 2005; 12(11): 895 - 899. [Abstract] [Full Text] [PDF]

				F. Puglisi, E. de Azambuja, G. de Castro Jr, and G. Demonty Shrinking the Tumor, Shrinking the Patient Sample Size: The Early Disclosure Dilemma J. Clin. Oncol., September 20, 2005; 23(27): 6803 - 6804. [Full Text] [PDF]

				A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, and L. A. Newman Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy Ann. Surg. Oncol., September 1, 2005; 12(9): 697 - 704. [Abstract] [Full Text] [PDF]

				E. P. Mamounas, A. Brown, S. Anderson, R. Smith, T. Julian, B. Miller, H. D. Bear, C. B. Caldwell, A. P. Walker, W. M. Mikkelson, et al. Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., April 20, 2005; 23(12): 2694 - 2702. [Abstract] [Full Text] [PDF]

				H. M. Kuerer and L. A. Newman Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Developments and Resolving Controversies J. Clin. Oncol., March 10, 2005; 23(8): 1698 - 1705. [Full Text] [PDF]

				H. S. Cody III Sentinel Lymph Node Biopsy for Breast Cancer: Does Anybody Not Need One? Ann. Surg. Oncol., December 1, 2003; 10(10): 1131 - 1132. [Full Text] [PDF]

				S. E. Singletary Candidates for Minimally Invasive Therapy of Breast Cancer: Redefining the Standards Ann. Surg. Oncol., July 1, 2003; 10(6): 591 - 592. [Full Text] [PDF]

				G. C. Balch, S. K. Mithani, K. R. Richards, R. D. Beauchamp, and M. C. Kelley Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer Ann. Surg. Oncol., July 1, 2003; 10(6): 616 - 621. [Abstract] [Full Text] [PDF]

				R. F. Hwang, S. Krishnamurthy, K. K. Hunt, N. Mirza, F. C. Ames, B. Feig, H. M. Kuerer, S. E. Singletary, G. Babiera, F. Meric, et al. Clinicopathologic Factors Predicting Involvement of Nonsentinel Axillary Nodes in Women With Breast Cancer Ann. Surg. Oncol., April 1, 2003; 10(3): 248 - 254. [Abstract] [Full Text] [PDF]

				J. Bonnema and C. J. H. van de Velde Sentinel lymph node biopsy in breast cancer Ann. Onc., October 1, 2002; 13(10): 1531 - 1537. [Abstract] [Full Text] [PDF]

				S. E. Singletary, C. Allred, P. Ashley, L. W. Bassett, D. Berry, K. I. Bland, P. I. Borgen, G. Clark, S. B. Edge, D. F. Hayes, et al. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer J. Clin. Oncol., September 1, 2002; 20(17): 3628 - 3636. [Abstract] [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease Oncologist, June 1, 2002; 7(3): 239 - 245. [Abstract] [Full Text] [PDF]

				V. Stearns, C. A. Ewing, R. Slack, M. F. Penannen, D. F. Hayes, and T. N. Tsangaris Sentinel Lymphadenectomy After Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla Except for Inflammatory Breast Cancer Ann. Surg. Oncol., April 1, 2002; 9(3): 235 - 242. [Abstract] [Full Text] [PDF]

				R. Rouzier, J.-M. Extra, J. Klijanienko, M.-C. Falcou, B. Asselain, A. Vincent-Salomon, P. Vielh, and E. Bourstyn Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes J. Clin. Oncol., March 1, 2002; 20(5): 1304 - 1310. [Abstract] [Full Text] [PDF]

				C. C. Solorzano, M. I. Ross, E. Delpassand, N. Mirza, J. S. Akins, H. M. Kuerer, F. Meric, F. C. Ames, L. Newman, B. Feig, et al. Utility of Breast Sentinel Lymph Node Biopsy Using Day-Before-Surgery Injection of High-Dose 99mTc-Labeled Sulfur Colloid Ann. Surg. Oncol., December 1, 2001; 8(10): 821 - 827. [Abstract] [Full Text] [PDF]

				G. Mariani, L. Moresco, G. Viale, G. Villa, M. Bagnasco, G. Canavese, J. Buscombe, H. W. Strauss, and G. Paganelli Radioguided Sentinel Lymph Node Biopsy in Breast Cancer Surgery J. Nucl. Med., August 1, 2001; 42(8): 1198 - 1215. [Abstract] [Full Text] [PDF]